The AKBA-enriched extract that matches the evidence exactly.
If you want to buy the version of boswellia the best trial actually used, Life Extension 5-LOXIN is it. The single most important number in this category isn't the milligrams of extract on the front of the bottle — it's the standardisation, and specifically the AKBA content. AKBA (acetyl-11-keto-β-boswellic acid) is the most potent 5-LOX-inhibiting fraction of the boswellic acids, and 5-Loxin is the branded extract enriched to ~30% AKBA that powered Sengupta 2008, the strongest boswellia osteoarthritis RCT.
Life Extension dose it at the clinical 100 mg, from a brand with a genuine longevity-supplement QC pedigree. It's pricier per gram than a whole-extract bottle because AKBA enrichment is the expensive part — but precision is exactly what you're paying for. Here's the full breakdown.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Boswellia guide →Uses 5-Loxin, the branded AKBA-enriched extract standardised to ~30% AKBA — the exact material validated in Sengupta 2008 and the highest-precision form in the category. This is the gold standard the whole-extract picks are measured against; full marks.
Dosed at 100 mg — the Sengupta 2008 lower arm, which produced significant improvement on its own. Loses a little because the trial's faster, larger effect came from the 250 mg arm, so reaching maximal onset means doubling to two caps. The 100 mg cap is trial-accurate; it just isn't the strongest arm by default.
Life Extension's QC pedigree is strong in the longevity-supplement space — GMP-certified manufacturing and a history of using branded clinical materials. Sourcing the actual 5-Loxin branded extract carries its own identity/potency documentation, an added quality signal for an adulteration-prone botanical.
Roughly $0.50 per 100 mg AKBA-enriched cap — meaningfully pricier per gram than the $0.08-0.09 whole-extract picks. That's the cost of AKBA enrichment, not a markup on boswellia. Reasonable for the precision, but it's the weakest criterion and the reason it isn't the budget call.
A clean, single-active AKBA cap — no fillers of note, no proprietary blend, nothing hiding the dose. Exactly what you want from a precision pick: you know precisely what you're taking, which makes it the easiest bottle in the category to stack with curcumin and omega-3.
“Contains 5-Loxin, the clinically studied AKBA-enriched boswellia extract.”
5-Loxin is the branded AKBA-enriched extract (~30% AKBA) used in Sengupta 2008 (PMID 18667054), the strongest boswellia osteoarthritis RCT. Life Extension sources the actual branded material, so the claim is literal — this is the trial extract, not a generic AKBA approximation.
“Standardised to a high AKBA concentration for maximum potency.”
AKBA is genuinely the most potent 5-LOX-inhibiting fraction of the boswellic acids, and 5-Loxin's ~30% AKBA standardisation is the highest-precision form in the consumer category. The potency framing is accurate and is the central reason this bottle ranks as the AKBA pick.
“Clinically shown to relieve osteoarthritis pain in as little as 7 days.”
True, but with an important dose caveat: the ~7-day onset in Sengupta 2008 came from the 250 mg/day arm, not the 100 mg single-cap dose Life Extension ships. At one cap you're at the slower-acting lower arm; reaching the fast-onset effect means taking two caps. Accurate about the extract, optimistic about the single-cap timeline.
“Manufactured to Life Extension's quality standards.”
Life Extension manufactures under GMP certification with published testing standards and a long track record of using branded clinical materials. Combined with the documented 5-Loxin source material, this is a credible, verifiable quality claim for a botanical extract.
Most of the boswellia category is approximation — whole extracts that contain AKBA without concentrating it, or resin that lists no standardisation at all. Life Extension 5-LOXIN is the exception: it uses the actual 5-Loxin branded extract (~30% AKBA) from Sengupta 2008, dosed at the trial's 100 mg. If your decision criterion is "buy the version the evidence validated," this is the unambiguous answer. Nothing else on the list can claim to be the literal trial material at the trial dose.
Sengupta 2008 tested two doses: 100 mg and 250 mg per day. Both worked, but the larger and faster effect — relief within about a week — came from the 250 mg arm. Life Extension ships 100 mg per cap, the lower arm. So the practical protocol is: start at one cap to confirm tolerance and response, then move to two caps (200 mg) if you want to approach the faster-acting higher arm. It's a minor inconvenience and it halves the bottle's lifespan, but it's how you get the quick onset the marketing references.
At ~$0.50 a cap, 5-LOXIN costs roughly five times more per cap than NOW's whole extract — and on paper it delivers less total boswellic acid. That sounds backwards until you understand what you're buying: not more boswellia, but more of the specific potent fraction (AKBA) the trial concentrated. A whole extract gives you more total acids at lower AKBA density; 5-Loxin gives you less total material at much higher AKBA density. For evidence-matching the trade is worth it; for raw cost-per-acid it isn't.
Boswellia's best use is often in a stack — with curcumin (NF-κB) and omega-3 (inflammation resolution) — because the three hit separate arms of the inflammatory cascade. 5-LOXIN is the cleanest stacking partner in the category: a single-active, precisely-dosed AKBA cap with nothing else in it, so you always know exactly what you're adding to the mix. Whole extracts with co-ingredients (like NOW's turmeric) muddy that math slightly. If you're building a deliberate three-pathway protocol, the precision here is a real practical advantage.
Doctor's Best AprèsFlex (#6) is the newer AKBA-enriched extract, formulated for better absorption. It's a legitimate near-tie on mechanism. But the distinction that breaks the tie for evidence-first buyers: 5-Loxin is the extract with the published RCT (Sengupta 2008) behind it, while AprèsFlex's enhanced-absorption advantage is supplier-backed with thinner independent comparison data. Both are top-precision-tier AKBA picks; 5-LOXIN is the one you choose if you weight "has the actual trial" over "newest absorption technology."
Life Extension 5-LOXIN is the bottle we point to when a reader says they want the version the best trial actually used. 5-Loxin is the branded AKBA-enriched extract (~30% AKBA) from Sengupta 2008, and Life Extension dose it at the clinical 100 mg from a brand with a real QC pedigree. The standardisation is the highest-precision in the category — you're buying the specific potent fraction the trial concentrated, not a whole-extract approximation. That precision is the whole point, and it's worth the premium for evidence-first buyers. Two things to plan for. First, the 100 mg cap is the trial's lower arm; double to two caps (200 mg) if you want the faster onset the 250 mg arm showed — which makes the 60-cap bottle a one-month supply. Second, it costs more per gram than a whole extract, because AKBA enrichment is the expensive part. If cost-per-acid is your priority, NOW (#1) or Swanson (#5) win on value; if you want the newest absorption technology, Doctor's Best AprèsFlex (#6) is the near-tie. But for matching the evidence exactly, this is the bottle — and it's the cleanest one to slot into a boswellia-plus-curcumin-plus-omega-3 stack.
The newer-generation AKBA-enriched extract, formulated for enhanced absorption over standard 5-Loxin, at a lower per-cap price. The near-tie if you want the latest extract technology rather than the one with the published trial.
See it on the list →A standardised whole extract (65% boswellic acids) plus turmeric at ~$11/month — the value pick. The right call if you want the lowest cost per gram of boswellic acids rather than maximal AKBA precision.
See it on the list →Combines standardised boswellia (BosPure) with high-absorption curcumin (BCM-95) in one bottle — two anti-inflammatory pathways at once. The pick if you'd rather not manage separate boswellia and curcumin bottles.
See it on the list →Randomised, double-blind, placebo-controlled crossover trial in knee-osteoarthritis patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved joint function, and increased walking distance versus placebo over 8 weeks. Establishes boswellia's osteoarthritis efficacy that 5-Loxin's AKBA enrichment refines.
The defining trial for this product: placebo-controlled study of 5-Loxin (the AKBA-enriched extract, ~30% AKBA) at 100 and 250 mg/day in knee osteoarthritis, with significant, dose-related reductions in pain and improvements in physical function — benefits appearing within ~7 days at 250 mg. Life Extension 5-LOXIN is the literal material from this study at the 100 mg dose.
